XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration and License Agreements (Details)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
non-clinicalStageCompound
undisclosedProgram
geneTherapyProgram
Mar. 31, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
preclinicalCandidate
$ / shares
shares
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Acquired in-process research and development $ 6.0 $ 143.9        
Unrealized gain on equity security investments 1.6 2.2        
Equity security investments 163.5         $ 161.9
Total revenues 515.3 $ 420.4        
Collaborative Arrangement | Common Stock | Voyager            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Beneficial ownership (as a percent)   19.90%        
Nxera | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 2,600.0          
Agreement termination, minimal contractual time (in days) 180 days          
Agreement termination, contractual time threshold (in days) 90 days          
Agreement termination by counterparty, contractual time threshold (in days) 365 days          
Agreement termination by counterparty, minimal contractual time (in days) 120 days          
Takeda | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 1,900.0          
Agreement termination, minimal contractual time (in days) 6 months          
Agreement termination, contractual time threshold (in days) 12 months          
Number of non-clinical stage compounds | non-clinicalStageCompound 3          
Idorsia | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 1,700.0          
Agreement termination, minimal contractual time (in days) 90 days          
Agreement termination, due to material breach (in days) 90 days          
Xenon | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 1,700.0          
Agreement termination, contractual time threshold (in days) 90 days          
Number of preclinical candidates | preclinicalCandidate         3  
Share price (in USD per share) | $ / shares     $ 31.855 $ 19.9755 $ 14.196  
Equity securities fair value (Level 3)       $ 4.6 $ 14.1  
Equity securities fair value (Level 1)     $ 7.7      
Xenon | Collaborative Arrangement | Common Stock            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Sale of stock (in shares) | shares     0.3 0.3 1.4  
Voyager | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Transfer, beneficial ownership, and voting restrictions period   3 years        
Unrealized gain on equity security investments $ 7.5 $ 9.3        
Equity security investments 79.8          
Voyager | Collaborative Arrangement | Common Stock            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Sale of stock (in shares) | shares   4.4     4.2  
2019 Voyager Agreement | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 1,300.0          
Agreement termination, minimal contractual time (in days) 180 days          
Agreement termination, contractual time threshold (in days) 1 year          
Share price (in USD per share) | $ / shares         $ 11.9625  
Equity securities fair value (Level 3)         $ 54.7  
Number of undisclosed programs | undisclosedProgram 2          
Research and development $ 5.0          
2023 Voyager Agreement | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 6,100.0          
Agreement termination, minimal contractual time (in days) 180 days          
Agreement termination, contractual time threshold (in days) 1 year          
Share price (in USD per share) | $ / shares   $ 8.88        
Equity securities fair value (Level 1)   $ 31.3        
Acquired in-process research and development   143.9        
Number of gene therapy programs | geneTherapyProgram 3          
Upfront payment   $ 175.0        
Board of directors maximum duration term (in years)   10 years        
MTPC | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Agreement termination, contractual time threshold (in days) 180 days          
Potential milestone payment receipts $ 30.0          
MTPC | Collaborative Arrangement | Minimum | Patents            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term (in years) 10 years          
AbbVie | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Agreement termination, contractual time threshold (in days) 180 days          
Potential milestone payment receipts $ 366.0          
AbbVie | Collaborative Arrangement | Royalty            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues $ 3.0 $ 3.7        
AbbVie | Collaborative Arrangement | Minimum | Patents            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term (in years) 10 years